Drug
Cpl500036 Low Dose
Cpl500036 Low Dose: highest development phase Phase 2, developed by Celon Pharma SA. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Celon Pharma SA
Trials
| Drug | Phase | Indication |
|---|---|---|
| CPL500036 - low dose NCT05278156 | Phase 2 | Schizophrenia |
| CPL500036 - low dose NCT05297201 | Phase 2 | Parkinson Disease |
Latest
No recent events.
Follow Cpl500036 Low Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.